As a systemic autoimmune disease, rheumatoid arthritis (RA) usually causes damage not
only to joints, but also to other tissues and organs including the heart, kidneys, lungs …

Rheumatoid arthritis (RA) is a chronic and systemic inflammatory disease affecting 0.5–1%
of the population worldwide. Interstitial lung disease (ILD) is a serious pulmonary …

Objective We provide evidence‐based recommendations regarding the treatment of
interstitial lung disease (ILD) in adults with systemic autoimmune rheumatic diseases …

Objective To assess the efficacy of abatacept (ABA) in RA patients with interstitial lung
disease (ILD)(RA-ILD). Methods This was an observational, multicentre study of RA-ILD …

Background Interstitial lung disease (ILD) is a serious complication that represents the
second leading cause of death in patients with rheumatoid arthritis (RA). Treatment of RA …

Rheumatoid arthritis (RA) is a systemic inflammatory disease, which primarily causes
symmetric polyarthritis. An extrarticolar involvement is common, and the commonly involved …

Background: Rheumatoid arthritis (RA)-related comorbidities, including cardiovascular
disease (CVD), osteoporosis (OP), and interstitial lung disease (ILD), are sub-optimally …

Background: The aim of this multicenter retrospective study was to investigate the
effectiveness and safety of the available JAK-inhibitors (JAKi) in patients with rheumatoid …

Objective: To prospectively evaluate the safety and efficacy profile of abatacept in patients
with rheumatoid arthritis–associated interstitial lung disease (RA-ILD). Methods: We …

Interstitial lung disease (ILD) is a common pulmonary complication of rheumatoid arthritis
(RA), causing significant morbidity and mortality. Optimal treatment for RA-ILD is not yet well …